Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANCOBON vs GYNIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Flucytosine is converted intracellularly to 5-fluorouracil, which inhibits fungal RNA and DNA synthesis by incorporating into RNA and inhibiting thymidylate synthase.
Coagulative necrosis of tissue via trichloroacetic acid; chemical cauterization of epithelial cells.
Treatment of systemic fungal infections (e.g., candidiasis, cryptococcosis) in combination with amphotericin B,Off-label: Serious infections caused by susceptible fungi
Cervical inflammation,Vaginal infections,Treatment of genital warts,Chemical cautery of skin lesions
50-150 mg/kg/day orally divided every 6 hours; intravenous dosing: 50-150 mg/kg/day divided every 12 hours.
1 vaginal tablet (100 mg) once daily at bedtime for 7 days
Terminal elimination half-life 2.5-6 hours (normal renal function). Prolonged to 30-250 hours in renal impairment (Cr Cl < 20 m L/min). Half-life correlates with creatinine clearance.
Terminal half-life is 2.5-3 hours in patients with normal renal function; prolonged to 6-8 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and up to 12-15 hours in severe renal impairment (Cr Cl <30 m L/min).
Deaminated to 5-fluorouracil in the body; further metabolized via same pathways as fluorouracil.
Not metabolized; acts locally via direct chemical action.
Primarily renal excretion of unchanged drug (75-90% within 24 hours). Less than 1% eliminated as 5-fluorouracil metabolite. Biliary/fecal excretion negligible.
Primarily renal (approximately 60-80% as unchanged drug) and biliary (20-30% as metabolites; unchanged drug not detected in bile). Fecal elimination accounts for <5%.
2-4% bound to plasma proteins (albumin).
Approximately 20-30% bound to albumin with negligible binding to alpha-1-acid glycoprotein.
0.6-0.9 L/kg, indicating distribution into total body water. Penetrates well into cerebrospinal fluid (50-100% of serum levels), aqueous humor, and peritoneal fluid.
Apparent Vd is 0.8-1.1 L/kg (range 0.6-1.3 L/kg), indicating extensive tissue distribution (e.g., lung, liver, bone).
Oral: 76-89% (well absorbed).
Oral: 85-95% (immediate-release) and 70-80% (sustained-release due to first-pass effect). Vaginal: 5-10% (minimal systemic absorption). IV: 100%.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: 50-100 mg/kg/day divided every 12-24 hours; GFR <10 m L/min: 50-100 mg/kg/day every 24-48 hours; intermittent hemodialysis: 50-100 mg/kg/day with each dialysis session; peritoneal dialysis: 50-100 mg/kg/day every 48 hours.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min: use with caution, consider alternative therapy.
No specific pediatric dosing based on Child-Pugh; use with caution and monitor liver function, potential reduced clearance. No standard adjustment defined.
Mild to moderate hepatic impairment (Child-Pugh A or B): no adjustment. Severe (Child-Pugh C): contraindicated.
Weight-based: 50-150 mg/kg/day orally divided every 6 hours, or 50-150 mg/kg/day intravenously divided every 12 hours; neonates: 25-100 mg/kg/day intravenously divided every 12 hours.
Not approved for use in pediatric patients.
Start at lower end of dosing range (50 mg/kg/day), adjust based on renal function; monitor for hematologic toxicity.
No dose adjustment required; use same as adult dosing.
None.
None.
Hematologic toxicity (leukopenia, thrombocytopenia); renal impairment requires dose adjustment; hepatotoxicity; monitoring of blood counts and renal function recommended.
Avoid contact with normal tissue; risk of chemical burns; not for use on neoplastic lesions.
Hypersensitivity to flucytosine or any component.
Hypersensitivity to trichloroacetic acid; pregnancy (relative); use on malignant tissue.
May be taken with food to reduce gastrointestinal upset. No specific dietary restrictions. Avoid alcohol.
No known food interactions with topical use. However, avoid concurrent use of iodine-containing supplements or medications, as it may increase systemic iodine load.
Flucytosine (ANCOBON) is teratogenic in animal studies, causing cleft palate, skeletal anomalies, and fetal resorption. Human data are limited; use in pregnancy only if clearly needed. Potential fetal risk in all trimesters. Contraindicated in first trimester unless life-threatening maternal infection.
First trimester: Inadequate human data; animal studies not available. Theoretical risk based on pharmacologic action. Second and third trimesters: No known fetal harm from topical use. Systemic absorption minimal.
Flucytosine is excreted into human breast milk; milk-to-plasma ratio approximately 1.0. Potential for serious adverse reactions in nursing infants; decision to discontinue nursing or drug depends on importance of drug to mother.
No data on excretion in human milk. Expected minimal systemic absorption. Use caution if applied to breast area. M/P ratio unknown.
Pregnancy may alter pharmacokinetics due to increased renal clearance and expanded plasma volume. Dose adjustment may be necessary; maintain serum concentrations within therapeutic range (trough 20-50 mcg/m L). Reduce dose in renal impairment, which may occur in pregnancy. No specific pregnancy dose guidelines; use with caution and monitor levels.
No dose adjustment necessary for topical use. Systemic absorption negligible.
Monitor for hepatotoxicity and bone marrow suppression; adjust dose in renal impairment (Cr Cl <50 m L/min requires dose interval extension). Obtain serum levels (desired peak 50-100 mcg/m L, trough <50 mcg/m L) to avoid toxicity. Use with caution in patients with pre-existing hematologic disorders or hepatic dysfunction. Synergistic with amphotericin B for cryptococcal meningitis; avoid concurrent use with nucleoside analogues (e.g., cytarabine) due to antagonism.
GYNIX (povidone-iodine) is a topical antiseptic. Avoid use in patients with iodine hypersensitivity or thyroid disorders (e.g., Hashimoto's thyroiditis). Prolonged use on large wounds may cause iodine absorption and thyroid dysfunction. Monitor for local irritation or allergic contact dermatitis.
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.,May cause nausea and vomiting; taking with food can help.,Report any signs of liver problems (yellowing skin/eyes, dark urine, severe abdominal pain) or unusual bruising/bleeding immediately.,Avoid alcohol while on this medication.,Use effective contraception during treatment; notify your doctor if you become pregnant.,Regular blood tests are required to monitor blood counts and liver function.
Do not use if you are allergic to iodine or have a thyroid condition.,For external use only. Avoid contact with eyes, mouth, or open wounds unless directed.,Discontinue and inform your doctor if you develop rash, itching, or swelling.,Store at room temperature away from light. Do not freeze or heat.,Not for use on deep or puncture wounds, or severe burns without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANCOBON vs GYNIX, answered by our medical review team.
ANCOBON is a Antifungal that works by Flucytosine is converted intracellularly to 5-fluorouracil, which inhibits fungal RNA and DNA synthesis by incorporating into RNA and inhibiting thymidylate synthase.. GYNIX is a Polyene Antifungal that works by Coagulative necrosis of tissue via trichloroacetic acid; chemical cauterization of epithelial cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANCOBON and GYNIX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANCOBON is: 50-150 mg/kg/day orally divided every 6 hours; intravenous dosing: 50-150 mg/kg/day divided every 12 hours.. The standard adult dose of GYNIX is: 1 vaginal tablet (100 mg) once daily at bedtime for 7 days. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANCOBON and GYNIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANCOBON is classified as Category C. Flucytosine (ANCOBON) is teratogenic in animal studies, causing cleft palate, skeletal anomalies, and fetal resorption. Human data are limited; use in pregnancy only if clearly nee. GYNIX is classified as Category C. First trimester: Inadequate human data; animal studies not available. Theoretical risk based on pharmacologic action. Second and third trimesters: No known fetal harm from topical . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.